Xconomy -- BG Medicine, a Waltham, MA-based developer of diagnostics technology, has withdrawn its second attempt at an initial public offering, after the deal failed to price, Dow Jones Newswires reports. Last week the firm set the targeted price range for its 4.75 million share IPO at $13 to $15 per share, giving it the potential to raise as much as $71.25 million. BG, which recently gained FDA clearance for its diagnostic test for chronic heart failure, also withdrew plans for an IPO in 2008.
